We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KORU Medical Systems Inc | NASDAQ:KRMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.48% | 2.11 | 2.08 | 2.39 | 2.17 | 2.08 | 2.12 | 79,885 | 22:59:00 |
Conference Call Scheduled for November 6 at 9:00 am ET
Q3 2019 Highlights
Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (the “Company”) today announced financial results for the third quarter (“Q3 2019”) ended September 30, 2019.
“Our strong performance continued through Q3 2019,” said Don Pettigrew, President and CEO of KORU Medical Systems. “Net sales increased over 45% from Q3 2018, representing the third consecutive quarter of record net sales, and gross margin improved to over 66%. We continue to penetrate our primary disease state end markets, the growth of which we attribute to increasing awareness and diagnosis of PIDD and expanded therapeutic indications for CIDP. Our Freedom Syringe Infusion System is also being utilized in multiple clinical trials associated with the development of new subcutaneous therapies, which is an important component of our long-term growth strategy.”
Mr. Pettigrew concluded, “We also completed two significant corporate developments: the listing of our common stock on NASDAQ effective October 17 and our corporate re-branding to KORU Medical Systems. We believe that both developments reflect our continuing growth as a public company, and the new life and beginnings we provide to patients worldwide.”
Q3 2019 Overview
Net sales rose 45.5% to $6.6 million in Q3 2019 from $4.5 million in Q3 2018. Growth was driven primarily by the Company’s continued success in expanding its presence in the Primary Immune Deficiency Disease (“PIDD”) and Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”) markets, as well as large orders from a domestic distributor, a new customer in Europe, and clinical trials. We cannot predict whether such large distributor orders or volume generally will continue in the future.
Gross profit in Q3 2019 rose to $4.4 million, or 66.2% of net sales, from $2.9 million, or 63.6% of net sales, in Q3 2018. Higher gross profit and gross margin were primarily driven by increased net sales and price increases.
Total operating expenses for Q3 2019 rose to $3.6 million from $2.4 million in Q3 2018. Selling, general & administrative (“SG&A”) expenses were $2.4 million, or 36.9% of net sales, compared to $1.9 million, or 42.2% of net sales in Q3 2018. Litigation costs increased to $0.9 million from $0.3 million in Q3 2018. The Company received its second consecutive favorable judgment in the litigation with EMED Technologies Corp. on August 30, 2019. KORU Medical Systems has filed motions for reimbursement of court costs and attorneys’ fees subsequent to the receipt of both judgements.
Net income for Q3 2019 rose to $0.7 million, or $0.02 per diluted share, from net income of $0.4 million, or $0.01 per diluted share, in Q3 2018.
Q3 2019 Adjusted EBITDA rose to $2.1 million, or 31.5% of net sales, from Adjusted EBITDA of $1.1 million, or 24.3% of net sales, in Q3 2018. Adjusted EBITDA excludes from net income: tax expense, depreciation and amortization, interest income, operating expenses associated with the company's organizational changes prior to March 31, 2019, litigation costs, and stock option expense.
Cash and equivalents as of September 30, 2019 was $5.1 million. Cash flow of $1.4 million for the first nine months of 2019 included a $2.1 million increase in accounts receivable reflecting a change in payment terms by a large distributor of our products from net 30 days to net 60 days, as well as a $0.6 million increase in inventory to commensurate with sales growth. These increases were partially offset by $1.5 million in proceeds realized from the maturation of a Certificate of Deposit in Q2 2019 and $0.5 million associated with the exercise of warrants and options during the period.
Non-GAAP Measures
This press release includes the non-GAAP financial measures of “Adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. A reconciliation of our non-GAAP measures is included in an attachment to this press release.
Conference Call
Management will host a conference call on Wednesday, November 6, 2019 at 9:00 am ET to discuss Q3 2019 results and business activities.
Interested parties may participate in the call by dialing:
Webcast registration: Click Here
Following the live call, a replay will be available for six months on the Company's website, www.korumedical.com under "Investor Relations."
About KORU Medical Systems
KORU Medical Systems manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information about the Company, please visit www.korumedical.com.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “continue” and "believe," and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
REPRO MED SYSTEMS, INC.
BALANCE SHEETS
September 30,
December 31,
2019
2018
(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$
5,129,028
$
3,738,803
Certificates of deposit
—
1,517,927
Accounts receivable less allowance for doubtful accounts of $36,609 at September 30, 2019 and $37,500 at December 31, 2018
3,546,634
1,425,854
Inventory
2,738,682
2,103,879
Prepaid expenses
453,151
246,591
TOTAL CURRENT ASSETS
11,867,495
9,033,054
Property and equipment, net
636,928
858,781
Patents, net of accumulated amortization of $273,846 and $239,581 at September 30, 2019 and December 31, 2018, respectively
786,164
632,156
Right of use assets, net
406,954
—
Deferred tax asset
—
1,466
Other assets
19,582
19,582
TOTAL ASSETS
$
13,717,123
$
10,545,039
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Deferred capital gain - current
$
—
$
3,763
Accounts payable
874,977
453,498
Accrued expenses
1,178,702
688,649
Accrued payroll and related taxes
111,359
421,714
Accrued tax liability
—
16,608
Finance lease liability - current
3,242
—
Operating lease liability - current
135,275
—
TOTAL CURRENT LIABILITIES
2,303,555
1,584,232
Deferred tax liability
133,097
—
Operating lease liability, net of current portion
271,679
—
TOTAL LIABILITIES
2,708,331
1,584,232
STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 42,228,658 and 40,932,911 shares issued, 39,491,427 and
38,195,680 shares outstanding at September 30, 2019 and December 31, 2018, respectively
422,286
409,329
Additional paid-in capital
5,985,636
4,595,214
Retained earnings
4,945,074
4,300,468
11,352,996
9,305,011
Less: Treasury stock, 2,737,231 shares at September 30, 2019 and December 31, 2018, respectively, at cost
(344,204
)
(344,204
)
TOTAL STOCKHOLDERS’ EQUITY
11,008,792
8,960,807
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$
13,717,123
$
10,545,039
The accompanying notes are an integral part of these financial statements
REPRO MED SYSTEMS, INC.
STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended
For the Nine Months Ended
September 30,
September 30,
2019
2018
2019
2018
NET SALES
$
6,617,397
$
4,547,187
$
16,940,487
$
13,082,737
Cost of goods sold
2,234,489
1,655,619
6,033,961
4,985,761
Gross Profit
4,382,908
2,891,568
10,906,526
8,096,976
OPERATING EXPENSES
Selling, general and administrative
2,441,381
1,917,127
6,976,684
5,513,727
Litigation
864,009
286,487
2,481,471
592,787
Research and development
170,260
126,923
450,454
160,735
Depreciation and amortization
82,774
78,345
252,594
228,900
Total Operating Expenses
3,558,424
2,408,882
10,161,203
6,496,149
Net Operating Profit
824,484
482,686
745,323
1,600,827
Non-Operating Income/(Expense)
Loss on currency exchange
(9,358
)
(5,842
)
(20,283
)
(16,256
)
Gain on disposal of fixed asset, net
—
6,000
49,740
6,000
Interest, net and other income, net
23,368
6,972
59,091
13,088
TOTAL OTHER INCOME
14,010
7,130
88,548
2,832
INCOME BEFORE TAXES
838,494
489,816
833,871
1,603,659
Income Tax Expense
(186,681
)
(103,263
)
(189,265
)
(337,956
)
NET INCOME
$
651,813
$
386,553
$
644,606
$
1,265,703
NET INCOME PER SHARE
Basic
$
0.02
$
0.01
$
0.02
$
0.03
Diluted
$
0.02
$
0.01
$
0.02
$
0.03
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic
39,022,298
38,194,682
38,534,021
38,104,393
Diluted
39,298,408
38,985,684
38,734,083
38,875,737
The accompanying notes are an integral part of these financial statements
REPRO MED SYSTEMS, INC.
STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended
September 30,
2019
2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income
$
644,606
$
1,265,703
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Stock based compensation expense
897,300
154,925
Depreciation and amortization
252,594
228,900
Deferred capital gain - building lease
(3,763
)
(16,860
)
Deferred taxes
134,563
10,834
Gain on disposal of fixed asset
(49,740
)
(6,000
)
Changes in operating assets and liabilities:
(Increase)/Decrease in accounts receivable
(2,120,780
)
351,319
Increase in inventory
(634,803
)
(290,722
)
Increase in prepaid expense and other assets
(206,560
)
(177,346
)
Increase in accounts payable
421,479
137,521
Decrease in accrued payroll and related taxes
(310,355
)
(213,700
)
Increase/(Decrease) in accrued expense
490,053
(30,823
)
Decrease in accrued tax liability
(16,608
)
(60,852
)
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES
(502,014
)
1,352,899
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for capital expenditures
(158,193
)
(188,006
)
Purchase of certificate of deposit
—
(1,500,000
)
Payments for patents
(188,274
)
(137,858
)
Proceeds on disposal of fixed asset
217,821
6,000
Proceeds from certificates of deposit
1,517,927
92,266
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES
1,389,281
(1,727,598
)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuances
508,900
51,250
Payment for cancelled shares
(2,820
)
(1,755
)
Finance lease
(3,122
)
—
NET CASH PROVIDED BY FINANCING ACTIVITIES
502,958
49,495
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS
1,390,225
(325,204
)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
3,738,803
3,974,536
CASH AND CASH EQUIVALENTS, END OF PERIOD
$
5,129,028
$
3,649,332
Supplemental Information
Cash paid during the periods for:
Interest
$
280
$
—
Taxes
$
103,465
$
378,000
NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation
$
256,525
$
103,333
The accompanying notes are an integral part of these financial statements
REPRO MED SYSTEMS, INC.
RECONCILIATION OF NON-GAAP MEASURES
Three Months Ended
Nine Months Ended
Reconciliation of GAAP Net Income
September 30,
September 30,
to Non-GAAP Adjusted EBITDA:
2019
2018
2019
2018
GAAP Net Income
$
651,813
$
386,553
$
644,606
$
1,265,703
Tax Expense
186,681
103,263
189,265
337,956
Depreciation/Amortization
82,774
78,345
252,594
228,900
Interest Income, Net
(23,368
)
(6,972
)
(59,091
)
(13,088
)
Reorganization Charges
—
232,471
354,926
383,668
Litigation
864,009
286,487
2,481,471
592,787
Stock Option Expense
324,135
24,922
640,775
51,592
Non-GAAP Adjusted EBITDA
$
2,086,044
$
1,105,069
$
4,504,546
$
2,847,518
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105006217/en/
The Equity Group Inc. Devin Sullivan Senior Vice President 212-836-9608 dsullivan@equityny.com
Kalle Ahl, CFA Vice President 212-836-9614 kahl@equityny.com
1 Year KORU Medical Systems Chart |
1 Month KORU Medical Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions